Acorda Therapeutics

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Global Ecology Corp. engages in the development, production and marketing of advanced waste remediation technologies that address universal environmental issues, which include organic soil revitalization, reduction of greenhouse gas emissions, solid waste remediation and point-of-use water purification solutions. The company was founded in 1993 and is headquartered in Las Vegas, NV.

FRANKFURT, Germany--(BUSINESS WIRE)--Merz Therapeutics announces today the successful acquisition of INBRIJA® (levodopa inhalation powder) and (F)AMPYRA® (fampridine), and related assets from Acorda Therapeutics, Inc. AMPYRA® (dalfampridine) is Food and Drug Administration (FDA) approved in the U.S. and commercialized as FAMPYRA in the European Union and other territories throughout the world. This transaction was conducted through a court-structured 363 sale under the U.S. Bankruptcy Code. The.

Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Delisting from Nasdaq.

Acorda Therapeutics Announces Delisting from Nasdaq

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Nasdaq Delisting Notification.

Acorda Therapeutics Announces Nasdaq Delisting Notification

Acorda Therapeutics (NASDAQ: ACOR ) stock is falling hard on Tuesday after the biopharmaceutical company signed a stalking horse asset purchase agreement with Merz Therapeutics. This agreement will have Merz Therapeutics acquire substantially all of the company's assets for $185 million.

Why Is Acorda Therapeutics (ACOR) Stock Down 72% Today?

Shares of Acorda Therapeutics ACOR, +1.96% fell late Monday after the company said it had filed for bankruptcy protection.

Acorda Therapeutics shares sink nearly 40% after bankruptcy filing

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement.

Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024.

Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024.

Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025.

Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

Acorda Therapeutics, Inc. (NASDAQ:ACOR ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - Founder, CEO, President & Director Michael Gesser - CFO Conference Call Participants Operator Welcome to Acorda Therapeutics Third Quarter 2023 Financial and Business Update. At this time, all participants are in a listen-only mode.

Acorda Therapeutics, Inc. (ACOR) Q3 2023 Earnings Call Transcript

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Third Quarter 2023 Financial Results.

Acorda Therapeutics Reports Third Quarter 2023 Financial Results

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023.

Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®.

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2023 Financial Results.

Acorda Therapeutics Reports Second Quarter 2023 Financial Results

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The FightersTM”.

Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023.

Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Tom Burns Elected to the Acorda Therapeutics Board of Directors.

Tom Burns Elected to the Acorda Therapeutics Board of Directors

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement.

Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement.

Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split.

Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split.

Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A.

Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A

Acorda Therapeutics, Inc. (NASDAQ:ACOR ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - Founder, CEO, President & Director Michael Gesser - CFO Conference Call Participants Operator Welcome to Acorda Therapeutics First Quarter 2023 Financial and Business Update. [Operator Instructions].

Acorda Therapeutics, Inc. (ACOR) Q1 2023 Earnings Call Transcript

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports First Quarter 2023 Financial Results.

Acorda Therapeutics Reports First Quarter 2023 Financial Results

Muscle Maker

Powerbridge Technologies Co Ltd

Prudent investors are now forced to reassess their portfolios and risk profiles. Indeed, for those invested in penny stocks, the promise of substantial returns is great.

News for Acorda Therapeutics Stock (ACOR)